A systematic review of intraluminal high dose rate brachytherapy in the management of malignant biliary tract obstruction and cholangiocarcinoma

Published:October 22, 2021DOI:https://doi.org/10.1016/j.radonc.2021.10.011

      Highlights

      • Cholangiocarcinoma is the most common cause of malignant biliary tract obstruction.
      • HDR intraluminal brachytherapy (ILBT) resulted in longer duration of stent patency.
      • HDR ILBT resulted in improved survival with low rates of complication and toxicity.
      • Future studies should consider HDR ILBT with stenting prior to chemotherapy.
      • This approach may improve patient quality of life, and potentially prolong survival.

      Abstract

      Purpose

      To conduct a systematic review evaluating the impact of high dose rate (HDR) intraluminal brachytherapy (ILBT) in the management of malignant biliary obstruction and cholangiocarcinoma with specific focus on stent patency, clinical outcomes and toxicities.

      Methods and materials

      A review of published articles was conducted using Medline, Embase and Cochrane databases using the search terms “bile duct carcinoma” or “cholangiocarcinoma” or “bile duct neoplasms” in combination with “brachytherapy” or “high dose rate brachytherapy” or “HDR brachytherapy”. Studies published in English and reporting outcomes of ≥10 patients were included in the review. Only the most recent experience was included if same patients were included in sequential publications.

      Results

      Seventeen studies were identified that met the inclusion criteria. Significant heterogeneity was observed in treatment regimens, which included use of surgery, external beam radiation (EBRT), and/or intra-arterial and intravenous chemotherapy in conjunction with ILBT. Nevertheless, among the included studies, use of ILBT appeared to result in longer duration of stent patency: 10 months with ILBT compared to 4–6 months without ILBT. A trend was observed towards prolonged local control and improved complete and partial response rates in patients treated with ILBT with or without EBRT. Weighted mean overall survival of patients treated with ILBT alone was 11.8 months compared to 10.5 months for those that received EBRT +/− chemotherapy in addition to ILBT. The included studies reported low complication rates and toxicity related to ILBT.

      Conclusion

      Brachytherapy can be an effective and safe tool in the management of malignant biliary tract obstruction in combination with stenting. Both retrospective and prospective studies have suggested improved outcomes when HDR ILBT is combined with percutaneous stenting.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic and Personal
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Radiotherapy and Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Rizvi S.
        • Khan S.A.
        • Hallemeier C.L.
        • Kelley R.K.
        • Gores G.J.
        Cholangiocarcinoma-evolving concepts and therapeutic strategies.
        Nat Rev Clin Oncol. 2018; 15: 95-111https://doi.org/10.1038/nrclinonc.2017.157
        • Chu D.
        • Adler D.G.
        Malignant biliary tract obstruction: Evaluation and therapy.
        JNCCN J Natl Compr Cancer Netw. 2010; 8: 1033-1044https://doi.org/10.6004/jnccn.2010.0075
        • Moss A.C.
        • Morris E.
        • Leyden J.
        • MacMathuna P.
        Do the benefits of metal stents justify the costs? A systematic review and meta-analysis of trials comparing endoscopic stents for malignant biliary obstruction.
        Eur J Gastroenterol Hepatol. 2007; 19: 1119-1124https://doi.org/10.1097/MEG.0b013e3282f16206
        • Fritz P.
        • Brambs H.
        • Schraube P.
        • Freund U.
        • Berns C.
        • Wannenmacher M.
        Combined external beam radiotherapy on bile duct carcinomas.
        Int J Radiat Oncol Biol Phys. 1994; 29: 855-861
        • van Berkel A.M.
        • van Marle J.
        • Groen A.K.
        • Bruno M.J.
        Mechanisms of biliary stent clogging: Confocal laser scanning and scanning electron microscopy.
        Endoscopy. 2005; 37: 729-734https://doi.org/10.1055/s-2005-870131
        • Chaurasia O.P.
        • Rauws E.A.J.
        • Fockens P.
        • Huibregtse K.
        Endoscopic techniques for retrieval of proximally migrated biliary stents: The Amsterdam experience.
        Gastrointest Endosc. 1999; 50: 780-785https://doi.org/10.1016/S0016-5107(99)70158-6
        • Wagner H.J.
        • Knyrim K.
        • Vakil N.
        • Klose K.J.
        Plastic endoprostheses versus metal stents in the palliative treatment of malignant hilar biliary obstruction. A prospective and randomized trial.
        Endoscopy. 1993; 25: 213-218https://doi.org/10.1055/s-2007-1010295
        • Tamada K.
        • Miyata T.
        • Tomiyama T.
        • Wada S.
        • Ohashi A.
        • Satoh Y.
        • et al.
        Placement of endoscopic naso-biliary drainage does not preclude subsequent percutaneous transhepatic biliary drainage.
        J Gastroenterol. 2000; 35: 445-449https://doi.org/10.1007/s005350070090
        • Rossi P.
        • Bezzi M.
        • Rossi M.
        • Adam A.
        • Chetty N.
        • Roddie M.E.
        • et al.
        Metallic stents in malignant biliary obstruction: results of a multicenter european study of 240 patients.
        J Vasc Interv Radiol. 1994; 5: 279-285https://doi.org/10.1016/S1051-0443(94)71483-4
        • Lee B.H.
        • Choe D.H.
        • Lee J.H.
        • Kim K.H.
        • Chin S.Y.
        Metallic stents in malignant biliary obstruction: Prospective long-term clinical results.
        Am J Roentgenol. 1997; 168: 741-745https://doi.org/10.2214/ajr.168.3.9057527
        • Baron T.H.
        • Mallery J.S.
        • Hirota W.K.
        • Goldstein J.L.
        • Jacobson B.C.
        • Leighton J.A.
        • et al.
        The role of endoscopy in the evaluation and treatment of patients with pancreaticobiliary malignancy.
        Gastrointest Endosc. 2003; 58: 643-649https://doi.org/10.1016/S0016-5107(03)01994-1
        • Sol Y.L.
        • Kim C.W.
        • Jeon U.B.
        • Lee N.K.
        • Kim S.
        • Kang D.H.
        • et al.
        Early infectious complications of percutaneous metallic stent insertion for malignant biliary obstruction.
        Am J Roentgenol. 2010; 194: 261-265https://doi.org/10.2214/AJR.09.2474
        • Shirabe K.
        • Shimada M.
        • Harimoto N.
        • Sugimachi K.
        • Yamashita Y.-I.
        • Tsujita E.
        • et al.
        Intrahepatic cholangiocarcinoma: Its mode of spreading and therapeutic modalities.
        Surgery. 2002; 131: S159-S164https://doi.org/10.1067/msy.2002.119498
        • Bruha R.
        • Petrtyl J.
        • Kubecova M.
        • et al.
        Intraluminal brachytherapy and self expandable stents in nonresectable biliary malignancies - The question of long-term palliation.
        Hepatogastroenterology. 2001; 48: 631-637
        • Chen Y.
        • Wang X.-L.
        • Yan Z.-P.
        • et al.
        HDR-192Ir intraluminal brachytherapy in treatment of malignant obstructive jaundice.
        World J Gastroenterol. 2004; 10: 3506-3510
        • Eschelman D.J.
        • Shapiro M.J.
        • Bonn J.
        • Sullivan K.L.
        • Alden M.E.
        • Hovsepian D.M.
        • et al.
        Malignant biliary duct obstruction: long-term experience with Gianturco stents and combined-modality radiation therapy.
        Radiology. 1996; 200: 717-724https://doi.org/10.1148/radiology.200.3.8756921
        • Foo M.L.
        • Gunderson L.L.
        • Bender C.E.
        • Buskirk S.J.
        External radiation therapy and transcatheter iridium in the treatment of extrahepatic bile duct carcinoma.
        Int J Radiat Oncol Biol Phys. 1997; 39: 929-935https://doi.org/10.1016/S0360-3016(97)00299-X
        • Válek V.
        • Kysela P.
        • Kala Z.
        • Kiss I.
        • Tomášek J.
        • Petera J.
        Brachytherapy and percutaneous stenting in the treatment of cholangiocarcinoma: A prospective randomised study.
        Eur J Radiol. 2007; 62: 175-179https://doi.org/10.1016/j.ejrad.2007.01.037
        • Xu X.
        • Li J.
        • Wu J.
        • Zhu R.
        • Ji W.
        A systematic review and meta-analysis of intraluminal brachytherapy versus stent alone in the treatment of malignant obstructive jaundice.
        Cardiovasc Intervent Radiol. 2018; 41: 206-217https://doi.org/10.1007/s00270-017-1827-6
      1. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi:10.1136/bmj.n71

      2. Page MJ, Moher D, Bossuyt PM, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372:n160. doi:10.1136/bmj.n160.

        • Buckley H.
        • Wilson C.
        • Ajithkumar T.
        High-dose-rate brachytherapy in the management of operable rectal cancer: A systematic review.
        Int J Radiat Oncol. 2017; 99: 111-127https://doi.org/10.1016/j.ijrobp.2017.05.023
        • Mattiucci G.C.
        • Autorino R.
        • Tringali A.
        • Perri V.
        • Balducci M.
        • Deodato F.
        • et al.
        A Phase I study of high-dose-rate intraluminal brachytherapy as palliative treatment in extrahepatic biliary tract cancer.
        Brachytherapy. 2015; 14: 401-404https://doi.org/10.1016/j.brachy.2014.12.002
        • Mosconi C.
        • Renzulli M.
        • Giampalma E.
        • et al.
        Unresectable perihilar cholangiocarcinoma: multimodal palliative treatment.
        Anticancer Res. 2013; 33: 2747-2753
        • Mayer R.
        • Stranzl H.
        • Prettenhofer U.
        • Quehenberger F.
        • Stucklschweiger G.
        • Winkler P.
        • et al.
        Palliative treatment of unresectable bile duct tumours.
        Acta Med Austriaca. 2003; 30: 10-12
        • Mukewar S.
        • Gupta A.
        • Baron T.
        • Gores G.
        • Furutani K.
        • Haddock M.
        • et al.
        Endoscopically inserted nasobiliary catheters for high dose-rate brachytherapy as part of neoadjuvant therapy for perihilar cholangiocarcinoma.
        Endoscopy. 2015; 47: 878-883https://doi.org/10.1055/s-0034-1392044
        • Nguyen N.-T.-A.
        • Timotin E.
        • Hunter R.
        • Sur R.K.
        High-dose rate intraluminal brachytherapy: An effective palliation for cholangiocarcinoma causing bile duct obstruction.
        Surg Oncol. 2018; 27: 625-629https://doi.org/10.1016/j.suronc.2018.07.004
        • Nomura M.
        • Yamakado K.
        • Nomoto Y.
        • Nakatsuka A.
        • Ii N.
        • Shoji K.
        • et al.
        Clinical efficacy of brachytherapy combined with external-beam radiotherapy and repeated arterial infusion chemotherapy in patients with unresectable extrahepatic bile duct cancer.
        Int J Oncol. 2002;
        • Qian X.-J.
        • Zhai R.-Y.
        • Dai D.-K.
        • Yu P.
        • Gao L.
        Treatment of malignant biliary obstruction by combined percutaneous transhepatic biliary drainage with local tumor treatment.
        World J Gastroenterol. 2006; 12: 331-335
        • Schleicher U.M.
        • Staatz G.
        • Alzen G.
        • Andreopoulos D.
        Combined external beam and intraluminal radiotherapy for irresectable Klatskin tumors.
        Strahlentherapie und Onkol. 2002; 178: 682-687https://doi.org/10.1007/s00066-002-0947-2
        • Shin H.S.
        • Seong J.
        • Kim W.C.
        • Lee H.S.
        • Moon S.R.
        • Lee I.J.
        • et al.
        Combination of external beam irradiation and high-dose-rate intraluminal brachytherapy for inoperable carcinoma of the extrahepatic bile ducts.
        Int J Radiat Oncol Biol Phys. 2003; 57: 105-112https://doi.org/10.1016/S0360-3016(03)00410-3
        • Singh V.
        • Kapoor R.
        • Solanki K.K.
        • Singh G.
        • Verma G.R.
        • Sharma S.C.
        Endoscopic intraluminal brachytherapy and metal stent in malignant hilar biliary obstruction: A pilot study.
        Liver Int. 2007; 27: 347-352https://doi.org/10.1111/j.1478-3231.2006.01439.x
        • Andrašina T.
        • Válek V.
        • Pánek J.
        • Kala Z.
        • Kiss I.
        • Tuček Š.
        • et al.
        Multimodal oncological therapy comprising stents, brachytherapy, and regional chemotherapy for cholangiocarcinoma.
        Gut Liver. 2010; 4: S82https://doi.org/10.5009/gnl.2010.4.S1.S82
        • Autorino R.
        • Mattiucci G.C.
        • Ardito F.
        • et al.
        Radiochemotherapy with gemcitabine in unresectable extrahepatic cholangiocarcinoma: long-term results of a phase II study.
        Anticancer Res. 2016; 36: 737-740
        • Golfieri R.
        • Giampalma E.
        • Fusco F.
        • Galuppi A.
        • Faccioli L.
        • Galaverni C.
        • et al.
        Unresectable hilar cholangiocarcinoma: multimodality treatment with percutaneous and intraluminal plus external radiotherapy.
        J Chemother. 2004; 16: 55-57https://doi.org/10.1080/1120009X.2004.11782386
        • Jain S.
        • Kataria T.
        • Bisht S.S.
        • Gupta D.
        • Vikraman S.
        • Baijal S.
        • et al.
        Malignant obstructive jaundice - Brachytherapy as a tool for palliation.
        J Contemp Brachyther. 2013; 2: 83-88https://doi.org/10.5114/jcb.2013.35563
        • Lu J.J.
        • Bains Y.S.
        • Abdel-Wahab M.
        • et al.
        High-dose_rate remote afterloading intracavitary brachytherapy for the treatment of extrahepatic biliary duct carcinoma.
        Cancer J. 2002; 8: 74-78
        • Fritz P.
        • Brambs H.-J.
        • Schraube P.
        • Freund U.
        • Berns C.
        • Wannenmacher M.
        Combined external beam radiotherapy and intraluminal high dose rate brachytherapy on bile duct carcinomas.
        Int J Radiat Oncol Biol Phys. 1994; 29: 855-861
        • Floyd J.
        • Mirza I.
        • Sachs B.
        • Perry M.C.
        Hepatotoxicity of chemotherapy.
        Semin Oncol. 2006; 33: 50-67https://doi.org/10.1053/j.seminoncol.2005.11.002
        • Koren G.
        • Beatty K.
        • Seto A.
        • Einarson T.R.
        • Lishner M.
        The effects of impaired liver function on the elimination of antineoplastic agents.
        Ann Pharmacother. 1992; 26: 363-371https://doi.org/10.1177/106002809202600311
        • Donelli M.G.
        • Zucchetti M.
        • Munzone E.
        • D’Incalci M.
        • Crosignani A.
        Pharmacokinetics of anticancer agents in patients with impaired liver function.
        Eur J Cancer. 1998; 34: 33-46https://doi.org/10.1016/S0959-8049(97)00340-7
      3. Gaspar LE, Winter K, Kocha WI, Coia LR, Herskovic A, Graham M. A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): final report. TL - 88. Cancer. 2000;88 VN-r(5):988-995. https://www.ncbi.nlm.nih.gov/pubmed/10699886.

        • McCarthy D.M.
        Sucralfate (editorial).
        N Engl J Med. 1991;
        • Valle J.
        • Wasan H.
        • Palmer D.H.
        • Cunningham D.
        • Anthoney A.
        • Maraveyas A.
        • et al.
        Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.
        N Engl J Med. 2010; 362: 1273-1281https://doi.org/10.1056/NEJMoa0908721
        • Park S.
        • Park J.Y.
        • Bang S.
        • Park S.W.
        • Chung J.B.
        • Song S.Y.
        Radiotherapy prolongs biliary metal stent patency in malignant pancreatobiliary obstructions.
        Gut Liver. 2013; 7: 480-485https://doi.org/10.5009/gnl.2013.7.4.480
        • Isayama H.
        • Tsujino T.
        • Nakai Y.
        • et al.
        Clinical benefit of radiation therapy and metallic stenting for unresectable hilar cholangiocarcinoma.
        World J Gastroenterol. 2012; 18: 2364-2370https://doi.org/10.3748/wjg.v18.i19.2364
        • Lee J.K.
        • Kwack W.K.
        • Lee S.H.
        • Jung J.H.
        • Kwon J.H.
        • Han I.W.
        • et al.
        Effect of external beam radiotherapy on patency of uncovered metallic stents in patients with inoperable bile duct cancer.
        Hepatobiliary Pancreat Dis Int. 2014; 13: 423-427https://doi.org/10.1016/S1499-3872(14)60282-4
        • Sung K.F.
        • Tsang N.M.
        • Tseng J.H.
        • Yeh C.T.
        Effective relief of obstructive jaundice in a patient with nonresectable icteric-type hepatocellular carcinoma by external beam radiation therapy: case report.
        Chang Gung Med J. 2001; 24: 114-118
      4. Kuhlmann JB, Euringer W, Spangenberg HC, et al. Treatment of unresectable cholangiocarcinoma. Eur J Gastroenterol Hepatol. January 2012:1. doi:10.1097/MEG.0b013e3283502241

        • Rafi S.
        • Piduru S.M.
        • El-Rayes B.
        • Kauh J.S.
        • Kooby D.A.
        • Sarmiento J.M.
        • et al.
        Yttrium-90 radioembolization for unresectable standard-chemorefractory intrahepatic cholangiocarcinoma: survival, efficacy, and safety study.
        Cardiovasc Intervent Radiol. 2013; 36: 440-448https://doi.org/10.1007/s00270-012-0463-4
      5. Fuks D, Bartoli E, Delcenserie R, et al. Biliary drainage, photodynamic therapy and chemotherapy for unresectable cholangiocarcinoma with jaundice. J Gastroenterol Hepatol. 2009;24(11):1745-1752. doi:10.1111/j.1440-1746.2009.05915.x

      6. NCCN Clinical Practice Guidelines in Oncology. Hepatobiliary Cancers. https://www.nccn.org/login?ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf. Published 2021.

        • Kaupp-Roberts S.D.
        • Yadegarfar G.
        • Friend E.
        • O'Donnell C.M.
        • Valle J.W.
        • Byrne C.
        • et al.
        Validation of the EORTC QLQ-BIL21 questionnaire for measuring quality of life in patients with cholangiocarcinoma and cancer of the gallbladder.
        Br J Cancer. 2016; 115: 1032-1038https://doi.org/10.1038/bjc.2016.284
        • Fayers P.
        • Bottomley A.
        Quality of life research within the EORTC-the EORTC QLQ-C30. European Organisation for Research and Treatment of Cancer.
        Eur J Cancer. 2002; 38: S125-S133https://doi.org/10.1016/s0959-8049(01)00448-8